SUMMARY
ZOVIRAX is the brand name for acyclovir, a synthetic nucleoside analog active against herpesviruses. Acyclovir sodium for injection is a sterile lyophilized powder for intravenous administration only.
Herpes Simplex Infections in Immunocompromised Patients: ZOVIRAX for Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients.
Initial Episodes of Herpes Genitalis: ZOVIRAX for Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients.
Herpes Simplex Encephalitis: ZOVIRAX for Injection is indicated for the treatment of herpes simplex encephalitis.
Neonatal Herpes Simplex Virus Infection: ZOVIRAX for Injection is indicated for the treatment of neonatal herpes infections.
Varicella-Zoster Infections in Immunocompromised Patients: ZOVIRAX for Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients.
|
NEWS HIGHLIGHTSMedia Articles Related to Zovirax Injection (Acyclovir)
Epiphany Announces Positive Results From Its Phase 2b Trial In Shingles
Source: Infectious Diseases / Bacteria / Viruses News From Medical News Today [2009.11.19]
Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash.
Published Studies Related to Zovirax Injection (Acyclovir)
Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. [2009.10.01]
BACKGROUND: It is uncertain whether episodic acyclovir will enhance ulcer healing if delivered at primary health care settings, because there is often a delay in treatment initiation... CONCLUSIONS: Addition of acyclovir to syndromic management will improve healing of genital ulcers and may potentially reduce HIV transmission in combination with other interventions.
Five-year follow-up on the effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis. [2009.09]
PURPOSE: To investigate the long-term effect of oral acyclovir administered during the first 6 months after penetrating keratoplasty (PK) for herpetic eye disease (HED)... CONCLUSION: The results of our study suggest that oral acyclovir prescribed during the first 6 months after PK for HED protects against clinically evident HED recurrences during the first 5 years following PK.
Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. [2009.07.15]
BACKGROUND: Little is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1)... CONCLUSION: Episodic therapy for herpes reduced the quantity of cervicovaginal HSV-2 DNA and slightly improved ulcer healing, but it did not decrease genital and plasma HIV-1 RNA loads. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00158483 .
Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. [2009.03]
BACKGROUND: Treatment of herpes simplex labialis (HSL) has been associated with modest benefits. This difficulty results from the rapid resolution of the disease accomplished by the immune system, which narrows the window of therapeutic opportunity. The immune response is also responsible for important clinical manifestations, including oedema and pain. The dual role of immune responses (protection, pathology) is well recognized in other infectious diseases. The addition of corticosteroids to antimicrobial agents has been associated with improvement in some of these diseases. OBJECTIVE: We evaluated the combination of oral valacyclovir plus topical clobetasol compared to placebo for recurrent HSL... CONCLUSIONS: This pilot study supports the addition of topical corticosteroids to an oral antiviral agent for the treatment of HSL. Larger studies need to confirm the safety and efficacy of this approach.
Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus. [2009.02]
CONCLUSIONS: The study did not demonstrate benefit of adjunctive valacyclovir for schizophrenia individuals with persistent symptoms who are CMV seropositive.
Clinical Trials Related to Zovirax Injection (Acyclovir)
Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS) [Completed]
To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303
gel in combination with acyclovir, relative to acyclovir alone, for the treatment of
recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and
neighboring areas, in patients with AIDS.
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection [Completed]
This double-blind, placebo-controlled study is designed to determine the long-term safety and
efficacy of concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy
alone, in the treatment of early symptomatic HIV infection. Efficacy will be evaluated by
monitoring the incidence, severity, and time of development of opportunistic infections and
other manifestations of advanced symptomatic HIV infection. The effects of the combination
and single AZT therapy on immune function and viral replication will also be evaluated. Study
participants will be monitored for evidence of toxicity or intolerance to concurrent AZT /
ACV administration and AZT therapy alone.
A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand [Completed]
Herpes infection is an important co-factor in HIV transmission. A recent meta-analysis
demonstrated that HSV infection contributed to a 2-fold increased risk of HIV transmission.
Suppressive therapy with acyclovir has been a method proposed to reduce HIV transmission. We
are conducting a randomized controlled cross-over trial to evaluate the effect of acyclovir
suppressive therapy on HIV genital shedding in women co-infected with HIV-1 and Herpes
Simplex Virus Type-2 (HSV-2) in Thailand.
Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers [Recruiting]
This study is designed to show bioequivalence between Current and New formulation of
Aciclovir cream 5% in keratin layer of the epidermis in Japanese Subjects
Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients [Completed]
To compare the efficacy of oral sorivudine (brovavir) and oral acyclovir for the treatment of
localized herpes zoster in HIV-infected patients.
HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster
virus ( VZV ) infections, also called shingles. Acyclovir, an approved drug, is widely used
to treat VZV infections in the HIV population. Since no data from controlled studies are
available to define the role of antiviral therapy for VZV infections in HIV-infected
patients, a study is needed to test the relative efficacy of brovavir, an experimental
antiviral drug, versus that of acyclovir.
|
